# FDA Inspection 1272748 - 3D Imaging Drug Design and Development - June 13, 2025

Source: https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/110c05b6-92ad-4ba6-a7b3-089d7293b2a5
Source feed: FDA_Inspections

> FDA Inspection 1272748 for 3D Imaging Drug Design and Development on June 13, 2025. Classification: Official Action Indicated (OAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1272748
- Company Name: 3D Imaging Drug Design and Development
- Inspection Date: 2025-06-13
- Classification: Official Action Indicated (OAI)
- Project Area: Drug Quality Assurance
- Product Type: Human Drugs
- Office Name: Dallas District Office

## Related Documents

- [FDA Inspection 1272748 - 2025-06-13](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/8e362411-467e-46a7-9f4f-d64498456d00)
- [FDA Inspection 1228168 - 2024-01-31](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/b62a272a-50d6-4a9e-99be-3d3008f0eb1d)
- [FDA Inspection 1009371 - 2017-04-20](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/64a48028-799f-499d-8317-f10bb4b44bfe)
- [FDA Inspection 1009371 - 2017-04-20](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/c6f3d6f1-1f20-4260-8e56-e2dbb100d33a)

Company: https://www.keypedia.com/companies/3d-imaging-drug-design-and-development/52a34c85-0fab-4e15-8980-ba031bb418ce

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9